Apogee Therapeutics (APGE) Preferred Stock Liabilities (2022 - 2023)
Apogee Therapeutics (APGE) posted quarterly Preferred Stock Liabilities of $148.5 million for Q3 2023, up 1717.35% year-over-year from $8.2 million in Q3 2022, and up 412.57% quarter-over-quarter from $29.0 million in Q2 2023.
Apogee Therapeutics (APGE) Preferred Stock Liabilities (2022 - 2023) Analysis & Trends
Apogee Therapeutics (APGE) has reported Preferred Stock Liabilities for 2 consecutive years, with $148.5 million the latest figure, recorded in Q3 2023.
- In Q3 2023, Preferred Stock Liabilities rose 1717.35% year-over-year to $148.5 million; the TTM figure through Sep 2023 stood at $148.5 million (up 1717.35% YoY), while the FY2022 annual figure was $29.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities grew to $148.5 million in Q3 2023 per APGE's latest filing, from $29.0 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $148.5 million in Q1 2023 and bottomed at $3.8 million in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Apogee Therapeutics | 10.14 Bn | 9.16 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 148.50 Mn |
| Jun 30, 2023 | 28.97 Mn |
| Mar 31, 2023 | 148.50 Mn |
| Dec 31, 2022 | 28.97 Mn |
| Sep 30, 2022 | 8.17 Mn |
| Jun 30, 2022 | 3.77 Mn |